Challenges in drug delivery to the tumors—nanoparticles in medicine

Abstract

Nanotechnology is a relatively young field of science that has found wide application in medicine, especially in oncology. It focuses on studying molecules at the atomic, molecular, and supramolecular levels, enabling the development of innovative therapeutic solutions. Thanks to research in this field, it has become possible to introduce nanoparticles (NPs) into therapy, specially designed molecules that release the drug in a precisely defined place. This approach allows for maintaining the appropriate therapeutic concentration of the drug substance in the body for a longer period of time. The use of NPs in the treatment of cancer diseases helps to overcome the limitations of traditional chemotherapy, such as systemic, toxic effects of drugs, lack of specificity towards cancer cells, and limited bioavailability. NPs can be used not only as drug carriers, but also as contrast agents enabling imaging at the molecular level. More accurate visualization of diseased tissues is possible thanks to the small size of NPs, optical properties, and the ability to accumulate in the tumor area. Additionally, the use of specific ligands allows detection of pathological changes at the cellular level, allowing for earlier detection of changes, which in turn increases the probability of complete recovery of the patient.

Keywords

Nanotechnology / nanoparticles / tumor / bioavailability

References

[1] Statistics Explained [Internet]. [cited 2024 Nov 22]. Available from: https://ec.europa.eu/eurostat/statistics—explained/index.php?title=Main_Page

[2] Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74: 229-63.

[3] Canavan ME, Wang X, Ascha MS, Miksad RA, Showalter TN, Calip GS, et al. Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors. JAMA Oncol. 2024; 10: 887-95.

[4] Zheng Y, Ye J, Li Z, Chen H, Gao Y. Recent progress in sono—photodynamic cancer therapy: From developed new sensitizers to nanotechnology—based efficacy—enhancing strategies. Acta Pharm Sin B. 2021; 11: 2197-219.

[5] Wang MD, Shin DM, Simons JW, Nie S. Nanotechnology for targeted cancer therapy. Expert Rev Anticancer Ther. 2007; 7: 833-7.

[6] Nie S, Xing Y, Kim GJ, Simons JW. Nanotechnology applications in cancer. Annu Rev Biomed Eng. 2007; 9: 257-88.

[7] Zhang Y, Li M, Gao X, Chen Y, Liu T. Nanotechnology in cancer diagnosis: progress, challenges and opportunities. J Hematol Oncol. 2019; 12: 137.

[8] Li B, Shao H, Gao L, Li H, Sheng H, Zhu L. Nano—drug co—delivery system of natural active ingredients and chemotherapy drugs for cancer treatment: a review. Drug Deliv. 2022; 29: 2130-61.

[9] Qi SS, Sun JH, Yu HH, Yu SQ. Co—delivery nanoparticles of anti—cancer drugs for improving chemotherapy efficacy. Drug Deliv. 2017; 24: 1909-26.

[10] Wei G, Wang Y, Yang G, Wang Y, Ju R. Recent progress in nanomedicine for enhanced cancer chemotherapy. Theranostics. 2021; 11: 6370-92.

[11] Zhu J, Wang J, Li Y. Recent advances in magnetic nanocarriers for tumor treatment. Biomed Pharmacother. 2023; 159: 114227.

[12] Zuo L, Feng Q, Han Y, Chen M, Guo M, Liu Z, et al. Therapeutic effect on experimental acute cerebral infarction is enhanced after nanoceria labeling of human umbilical cord mesenchymal stem cells. Ther Adv Neurol Disord. 2019; 12: 1756286419859725.

[13] Kim SE, Lee BR, Lee H, Jo SD, Kim H, Won YY, et al. Near—Infrared Plasmonic Assemblies of Gold Nanoparticles with Multimodal Function for Targeted Cancer Theragnosis. Sci Rep. 2017; 7: 17327.

[14] Zhuo S, Zhang F, Yu J, Zhang X, Yang G, Liu X. pH—Sensitive Biomaterials for Drug Delivery. Molecules. 2020; 25: 5649.

[15] Zuo L, Nie W, Yu S, Zhuang W, Wu G, Liu H, et al. Smart Tumor—Cell—Derived Microparticles Provide On—Demand Photosensitizer Synthesis and Hypoxia Relief for Photodynamic Therapy. Angew Chem Int Ed Engl. 2021; 60: 25365—71.

[16] Amreddy N, Babu A, Muralidharan R, Panneerselvam J, Srivastava A, Ahmed R, et al. Recent Advances in Nanoparticle—Based Cancer Drug and Gene Delivery. Adv Cancer Res. 2018; 137: 115-70.

[17] Ho BN, Pfeffer CM, Singh ATK. Update on Nanotechnology—based Drug Delivery Systems in Cancer Treatment. Anticancer Res. 2017; 37: 5975-81.

[18] Barenholz Y. Doxil® — the first FDA—approved nano—drug: lessons learned. J Control Release. 2012; 160: 117-34.

[19] Rosenblum D, Peer D. Omics—based nanomedicine: the future of personalized oncology. Cancer Lett. 2014; 352: 126—36.

[20] Lee H, Shields AF, Siegel BA, Miller KD, Krop I, Ma CX, et al. ⁶⁴Cu—MM—302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer. Clin Cancer Res. 2017; 23: 4190-202.

[21] Tang L, Fan TM, Borst LB, Cheng J. Synthesis and biological response of size—specific, monodisperse drug—silica nanoconjugates. ACS Nano. 2012; 6: 3954-66.

[22] Smith BR, Kempen P, Bouley D, Xu A, Liu Z, Melosh N, et al. Shape matters: intravital microscopy reveals surprising geometrical dependence for nanoparticles in tumor models of extravasation. Nano Lett. 2012; 12: 3369-77.

[23] Anselmo AC, Zhang M, Kumar S, Vogus DR, Menegatti S, Helgeson ME, et al. Elasticity of nanoparticles influences their blood circulation, phagocytosis, endocytosis, and targeting. ACS Nano. 2015; 9: 3169-77.

[24] Sykes EA, Dai Q, Sarsons CD, Chen J, Rocheleau JV, Hwang DM, et al. Tailoring nanoparticle designs to target cancer based on tumor pathophysiology. Proc Natl Acad Sci U S A. 2016; 113: E1142-51.

[25] Zu Y, Zhao Q, Zhao X, Zu S, Meng L. Process optimization for the preparation of oligomycin—loaded folate—conjugated chitosan nanoparticles as a tumor—targeted drug delivery system using a two—level factorial design method. Int J Nanomedicine. 2011; 6: 3429—41.

[26] Cui Y, Zhang M, Zeng F, Jin H, Xu Q, Huang Y. Dual—Targeting Magnetic PLGA Nanoparticles for Codelivery of Paclitaxel and Curcumin for Brain Tumor Therapy. ACS Appl Mater Interfaces. 2016; 8: 32159-69.

[27] Peer D, Margalit R. Tumor—targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models. Neoplasia. 2004; 6: 343-53.

[28] Park J, Choi Y, Chang H, Um W, Ryu JH, Kwon IC. Alliance with EPR Effect: Combined Strategies to Improve the EPR Effect in the Tumor Microenvironment. Theranostics. 2019; 9: 8073-90.

[29] Dhaliwal A, Zheng G. Improving accessibility of EPR—insensitive tumor phenotypes using EPR—adaptive strategies: Designing a new perspective in nanomedicine delivery. Theranostics. 2019; 9: 8091-108.

[30] Xu R, Zhang G, Mai J, Deng X, Segura—Ibarra V, Wu S, et al. An injectable nanoparticle generator enhances delivery of cancer therapeutics. Nat Biotechnol. 2016; 34: 414—8.

[31] Huang B, Abraham WD, Zheng Y, Bustamante López SC, Luo SS, Irvine DJ. Active targeting of chemotherapy to disseminated tumors using nanoparticle—carrying T cells. Sci Transl Med. 2015; 7: 291ra94.

[32] Bazak R, Houri M, El Achy S, Kamel S, Refaat T. Cancer active targeting by nanoparticles: a comprehensive review of literature. J Cancer Res Clin Oncol. 2015; 141: 769-84.

[33] Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, et al. Antibody targeting of long—circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006; 66: 6732—40.

[34] Wang X, Qiu Y, Wang M, Zhang C, Zhang T, Zhou H, et al. Endocytosis and Organelle Targeting of Nanomedicines in Cancer Therapy. Int J Nanomedicine. 2020; 15: 9447—67.

[35] Patel S, Kim J, Herrera M, Mukherjee A, Kabanov AV, Sahay G. Brief update on endocytosis of nanomedicines. Adv Drug Deliv Rev. 2019; 144: 90-111.

[36] Chen K, Li X, Zhu H, Gong Q, Luo K. Endocytosis of Nanoscale Systems for Cancer Treatments. Curr Med Chem. 2018; 25: 3017—35.

[37] Qie Y, Yuan H, von Roemeling CA, Chen Y, Liu X, Shih KD, et al. Surface modification of nanoparticles enables selective evasion of phagocytic clearance by distinct macrophage phenotypes. Sci Rep. 2016; 6: 26269.

[38] McMahon HT, Boucrot E. Molecular mechanism and physiological functions of clathrin—mediated endocytosis. Nat Rev Mol Cell Biol. 2011; 12: 517—33.

[39] Yameen B, Choi WI, Vilos C, Swami A, Shi J, Farokhzad OC. Insight into nanoparticle cellular uptake and intracellular targeting. J Control Release. 2014; 190: 485-99.

[40] Wang Y, Huang L. A window onto siRNA delivery. Nat Biotechnol. 2013; 31: 611—2.

[41] Lear JD, DeGrado WF. Membrane binding and conformational properties of peptides representing the NH2 terminus of influenza HA—2. J Biol Chem. 1987; 262: 6500—5.

[42] Gray C, Tatulian SA, Wharton SA, Tamm LK. Effect of the N—terminal glycine on the secondary structure, orientation, and interaction of the influenza hemagglutinin fusion peptide with lipid bilayers. Biophys J. 1996; 70: 2275-86.

[43] Sahay G, Querbes W, Alabi C, Eltoukhy A, Sarkar S, Zurenko C, et al. Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat Biotechnol. 2013; 31: 653—8.

[44] Zhang H, Sheng D, Han Z, Zhang L, Sun G, Yang X, et al. Doxorubicin—liposome combined with clodronate—liposome inhibits hepatocellular carcinoma through the depletion of macrophages and tumor cells. Int J Pharm. 2022; 629: 122346.

[45] Souza IDL, Saez V, Mansur CRE. Lipid nanoparticles containing coenzyme Q10 for topical applications: An overview of their characterization. Colloids Surf B Biointerfaces. 2023; 230: 113491.

[46] Yeapuri P, Olson KE, Lu Y, Abdelmoaty MM, Namminga KL, Markovic M, et al. Development of an extended half—life GM—CSF fusion protein for Parkinson’s disease. J Control Release. 2022; 348: 951-65.

[47] Ziraksaz Z, Nomani A, Soleimani M, Bakhshandeh B, Arefian E, Haririan I, et al. Evaluation of cationic dendrimer and lipid as transfection reagents of short RNAs for stem cell modification. Int J Pharm. 2013; 448: 231—8.

[48] Patil SD, Rhodes DG, Burgess DJ. Anionic liposomal delivery system for DNA transfection. AAPS J. 2004; 6: e29.

[49] Kanwal U, Irfan Bukhari N, Ovais M, Abass N, Hussain K, Raza A. Advances in nano—delivery systems for doxorubicin: an updated insight. J Drug Target. 2018; 26: 296-310.

[50] Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances and Challenges of Liposome Assisted Drug Delivery. Front Pharmacol. 2015; 6: 286.

[51] Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery — a review of the state of the art. Eur J Pharm Biopharm. 2000; 50: 161-77.

[52] Dong Y, Ng WK, Shen S, Kim S, Tan RB. Solid lipid nanoparticles: continuous and potential large—scale nanoprecipitation production in static mixers. Colloids Surf B Biointerfaces. 2012; 94: 68-72.

[53] Khosa A, Reddi S, Saha RN. Nanostructured lipid carriers for site—specific drug delivery. Biomed Pharmacother. 2018; 103: 598-613.

[54] Wu M, Fan Y, Lv S, Xiao B, Ye M, Zhu X. Vincristine and temozolomide combined chemotherapy for the treatment of glioma: a comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery. Drug Deliv. 2016; 23: 2720—5.

[55] Banerjee S, Kundu A. Lipid—drug conjugates: a potential nanocarrier system for oral drug delivery applications. Daru. 2018; 26: 65-75.

[56] Shinde G, Shiyani S, Shelke S, Chouthe R, Kulkarni D, Marvaniya K. Enhanced brain targeting efficiency using 5—FU (fluorouracil) lipid—drug conjugated nanoparticles in brain cancer therapy. Prog Biomater. 2020; 9: 259-75.

[57] Mukherjee A, Waters AK, Kalyan P, Achrol AS, Kesari S, Yenugonda VM. Lipid—polymer hybrid nanoparticles as a next—generation drug delivery platform: state of the art, emerging technologies, and perspectives. Int J Nanomedicine. 2019; 14: 1937-52.

[58] Yang P, Zhang L, Wang T, Liu Q, Wang J, Wang Y, et al. Doxorubicin and Edelfosine Combo—Loaded Lipid—Polymer Hybrid Nanoparticles for Synergistic Anticancer Effect Against Drug—Resistant Osteosarcoma. Onco Targets Ther. 2020; 13: 8055-67.

[59] Arvizo RR, Bhattacharyya S, Kudgus RA, Giri K, Bhattacharya R, Mukherjee P. Intrinsic therapeutic applications of noble metal nanoparticles: past, present and future. Chem Soc Rev. 2012; 41: 2943-70.

[60] Divya KP, Karthikeyan R, Sinduja B, Anancia Grace A, John SA, Hahn JH, et al. Carbon dots stabilized silver—lipid nano hybrids for sensitive label free DNA detection. Biosens Bioelectron. 2019; 133: 48-54.

[61] Rengan AK, Bukhari AB, Pradhan A, Malhotra R, Banerjee R, Srivastava R, et al. In vivo analysis of biodegradable liposome gold nanoparticles as efficient agents for photothermal therapy of cancer. Nano Lett. 2015; 15: 842-8.

[62] Gaucher G, Dufresne MH, Sant VP, Kang N, Maysinger D, Leroux JC. Block copolymer micelles: preparation, characterization and application in drug delivery. J Control Release. 2005; 109: 169-88.

[63] Chang CE, Hsieh CM, Huang SC, Su CY, Sheu MT, Ho HO. Lecithin—Stabilized Polymeric Micelles (L_sbPMs) for Delivering Quercetin: Pharmacokinetic Studies and Therapeutic Effects of Quercetin Alone and in Combination with Doxorubicin. Sci Rep. 2018; 8: 17640.

[64] Kunde SS, Wairkar S. Targeted delivery of albumin nanoparticles for breast cancer: A review. Colloids Surf B Biointerfaces. 2022; 213: 112422.

[65] Zoa A, Yang Y, Huang W, Yang J, Wang J, Wang H, et al. High expression of hypoxia—inducible factor 1—alpha predicts poor prognosis in pancreatic ductal adenocarcinoma: a meta—analysis and database validation protocol. Transl Cancer Res. 2022; 11: 3080-91.

[66] Zumaya ALV, Pavlíčková VS, Rimpelová S, Štějdířová M, Fulem M, Křížová I, et al. PLGA—based nanocarriers for combined delivery of colchicine and purpurin 18 in cancer therapy: Multimodal approach employing cancer cell spheroids. Int J Pharm. 2024; 657: 124170.

[67] Zu YG, Yuan S, Zhao XH, Zhang Y, Zhang XN, Jiang R. Preparation, activity and targeting ability evaluation in vitro on folate mediated epigallocatechin—3—gallate albumin nanoparticles. Yao Xue Xue Bao. 2009; 44: 525—31. Chinese.

[68] Rafiei P, Haddadi A. Pharmacokinetic Consequences of PLGA Nanoparticles in Docetaxel Drug Delivery. Pharm Nanotechnol. 2017; 5: 3-23.

[69] Lee SB, Park JM, Park R, Choi HE, Hong SW, Kim KS. Synergistic chemo—photothermal treatment via MXene—encapsulated nanoparticles for targeted melanoma therapy. J Control Release. 2025; 382: 113729.

[70] Su Y, Zhang B, Sun R, Liu W, Zhu Q, Zhang X, et al. PLGA—based biodegradable microspheres in drug delivery: recent advances in research and application. Drug Deliv. 2021; 28: 1397-418.

[71] Fredenberg S, Wahlgren M, Reslow M, Axelsson A. The mechanisms of drug release in poly(lactic—co—glycolic acid)—based drug delivery systems—a review. Int J Pharm. 2011; 415: 34-52.

[72] Pramual S, Lirdprapamongkol K, Atjanasuppat K, Chaisuriya P, Niamsiri N, Svasti J. PLGA—Lipid Hybrid Nanoparticles for Overcoming Paclitaxel Tolerance in Anoikis—Resistant Lung Cancer Cells. Molecules. 2022; 27: 8295.

[73] Umar S, Zahra M, Akhter MS, Waseem A. Novel surfactant stabilized PLGA cisplatin nanoparticles for drug delivery applications. Turk J Chem. 2021; 45: 1786-95.

[74] Wang B, Yu XC, Xu SF, Xu M. Paclitaxel and etoposide co—loaded polymeric nanoparticles for the effective combination therapy against human osteosarcoma. J Nanobiotechnology. 2015; 13: 22.

[75] Sonam Dongsar T, Tsering Dongsar T, Molugulu N, Annadurai S, Wahab S, Gupta N, et al. Targeted therapy of breast tumor by PLGA—based nanostructures: The versatile function in doxorubicin delivery. Environ Res. 2023; 233: 116455.

[76] Xu X, Zhang X, Li R, Yang X, Fu P, Feng R, et al. Platelet Membrane—Coated Curcumin—PLGA Nanoparticles Promote Astrocyte—Neuron Transdifferentiation for Intracerebral Hemorrhage Treatment. Small. 2024; 20: e2311128.

[77] He X, Liu J, Song T, Sun Y, Lu X, Li N, et al. Effects of water—soluble additive on the release profile and pharmacodynamics of triptorelin loaded in PLGA microspheres. Drug Dev Ind Pharm. 2023; 49: 357-66.

[78] Rençber S, Aydın Köse F, Karavana SY. Dexamethasone loaded PLGA nanoparticles for potential local treatment of oral precancerous lesions. Pharm Dev Technol. 2020; 25: 149—58.

[79] Cho H, Kwon GS. Thermosensitive poly—(d,l—lactide—co—glycolide)—block—poly(ethylene glycol)—block—poly—(d,l—lactide—co—glycolide) hydrogels for multi—drug delivery. J Drug Target. 2014; 22: 669-77.

[80] Kim SY, Jo MJ, Yoon MS, Jin CE, Shin YB, Lee JM, et al. Gemcitabine and rapamycin—loaded mixed polymeric thermogel for metastatic pancreatic cancer therapy. J Control Release. 2023; 360: 796-809.

[81] Chen Y, Zheng XL, Fang DL, Yang Y, Zhang JK, Li HL, et al. Dual agent loaded PLGA nanoparticles enhanced antitumor activity in a multidrug—resistant breast tumor xenograft model. Int J Mol Sci. 2014; 15: 2761—72.

[82] Mittal P, Saharan A, Verma R, Altalbawy FMA, Alfaidi MA, Batiha GE, et al. Dendrimers: A New Race of Pharmaceutical Nanocarriers. Biomed Res Int. 2021; 2021: 8844030.

[83] Bober Z, Bartusik—Aebisher D, Aebisher D. Application of Dendrimers in Anticancer Diagnostics and Therapy. Molecules. 2022; 27: 3237.

[84] Palmerston Mendes L, Pan J, Torchilin VP. Dendrimers as Nanocarriers for Nucleic Acid and Drug Delivery in Cancer Therapy. Molecules. 2017; 22: 1401.

[85] Zhong Q, Bielski ER, Rodrigues LS, Brown MR, Reineke JJ, da Rocha SR. Conjugation to Poly(amidoamine) Dendrimers and Pulmonary Delivery Reduce Cardiac Accumulation and Enhance Antitumor Activity of Doxorubicin in Lung Metastasis. Mol Pharm. 2016; 13: 2363—75.

[86] Zare H, Ahmadi S, Ghasemi A, Ghanbari M, Rabiee N, Bagherzadeh M, et al. Carbon Nanotubes: Smart Drug/Gene Delivery Carriers. Int J Nanomedicine. 2021; 16: 1681-706.

[87] Das SS, Bharadwaj P, Bilal M, Barani M, Rahdar A, Taboada P, et al. Stimuli—Responsive Polymeric Nanocarriers for Drug Delivery, Imaging, and Theragnosis. Polymers (Basel). 2020; 12: 1397.

[88] Kasai T, Umeda Y, Ohnishi M, Kondo H, Takeuchi T, Aiso S, et al. Thirteen—week study of toxicity of fiber—like multi—walled carbon nanotubes with whole—body inhalation exposure in rats. Nanotoxicology. 2015; 9: 413-22.

[89] Yan H, Xue Z, Xie J, Dong Y, Ma Z, Sun X, et al. Toxicity of Carbon Nanotubes as Anti—Tumor Drug Carriers. Int J Nanomedicine. 2019; 14: 10179—94.

[90] Kateb B, Chiu K, Black KL, Yamamoto V, Khalsa B, Ljubimova JY, et al. Nanoplatforms for constructing new approaches to cancer treatment, imaging, and drug delivery: what should be the policy? Neuroimage. 2011; 54: S106—24.

[91] Kang MS, Lee SY, Kim KS, Han DW. State of the Art Biocompatible Gold Nanoparticles for Cancer Theragnosis. Pharmaceutics. 2020; 12: 701.

[92] Zhang C, Zhao Y, Zhang E, Jiang M, Zhi D, Chen H, et al. Co—delivery of paclitaxel and anti—VEGF siRNA by tripeptide lipid nanoparticle to enhance the anti—tumor activity for lung cancer therapy. Drug Deliv. 2020; 27: 1397-411.

[93] Zhou Z, Liu Y, Jiang X, Zheng C, Luo W, Xiang X, et al. Metformin modified chitosan as a multi—functional adjuvant to enhance cisplatin—based tumor chemotherapy efficacy. Int J Biol Macromol. 2023; 224: 797-809.

[94] Zhou Z, Wang H, Li J, Jiang X, Li Z, Shen J. Recent progress, perspectives, and issues of engineered PD—L1 regulation nano—system to better cure tumor: A review. Int J Biol Macromol. 2024; 254: 127911.

[95] Zheng C, Luo W, Liu Y, Chen J, Deng H, Zhou Z, et al. Killing three birds with one stone: Multi—stage metabolic regulation mediated by clinically usable berberine liposome to overcome photodynamic immunotherapy resistance. Chem Eng J. 2023; 454: 140164.